Myriad Genetics Announces Inclusion Of Breast Density To MyRisk With RiskScore Breast Cancer Risk Assessment
Portfolio Pulse from Happy Mohamed
Myriad Genetics has announced that its MyRisk Hereditary Cancer Test with RiskScore now includes breast density, personal/family clinical history, and a polygenic risk score. This is expected to provide a more comprehensive breast cancer risk assessment and help detect cancer in its early stages. The Federal Drug Administration recently updated mammography regulations requiring facilities to notify patients about their breast density by September 2024.
July 24, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics' inclusion of breast density in its MyRisk Hereditary Cancer Test with RiskScore is expected to provide a more comprehensive breast cancer risk assessment. This could potentially increase the demand for the test and positively impact the company's revenues.
The inclusion of breast density in Myriad Genetics' MyRisk test is a significant development. It aligns with the recent FDA regulations and could potentially increase the demand for the test, as it provides a more comprehensive risk assessment. This could lead to increased revenues for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100